365 related articles for article (PubMed ID: 22311160)
1. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
2. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
3. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma.
Kwon J; Yoon HJ; Kim JH; Lee TS; Song IH; Lee HW; Kang MC; Park JH
Oncol Rep; 2014 Sep; 32(3):1188-92. PubMed ID: 24993015
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
De Cesare M; Lauricella C; Veronese SM; Cominetti D; Pisano C; Zunino F; Zaffaroni N; Zuco V
Clin Cancer Res; 2014 Feb; 20(4):995-1006. PubMed ID: 24327272
[TBL] [Abstract][Full Text] [Related]
6. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
[TBL] [Abstract][Full Text] [Related]
8. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.
Liu X; Guo WJ; Zhang XW; Cai X; Tian S; Li J
Cancer Chemother Pharmacol; 2011 Oct; 68(4):871-8. PubMed ID: 21286718
[TBL] [Abstract][Full Text] [Related]
10. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway.
Cao S; Xia M; Mao Y; Zhang Q; Donkor PO; Qiu F; Kang N
Int J Oncol; 2016 Nov; 49(5):2075-2087. PubMed ID: 27667173
[TBL] [Abstract][Full Text] [Related]
11. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
16. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
17. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.
Kawaguchi Y; Kono K; Mimura K; Mitsui F; Sugai H; Akaike H; Fujii H
Br J Cancer; 2007 Aug; 97(4):494-501. PubMed ID: 17622245
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
[TBL] [Abstract][Full Text] [Related]
19. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
20. Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo.
Kobunai T; Watanabe T; Fukusato T
Anticancer Res; 2011 Nov; 31(11):3691-6. PubMed ID: 22110188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]